Cancer drug therapy and stochastic modeling of “nano-motors”
Received 10 July 2018
Accepted for publication 30 August 2018
Published 15 October 2018 Volume 2018:13 Pages 6429—6440
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Thomas Webster
Lubna Sherin,1 Shabieh Farwa,2 Ayesha Sohail,3 Zhiwu Li,4,5 O Anwar Bég6
1Department of Chemistry, COMSATS University Islamabad, Lahore 54000, Pakistan; 2Department of Mathematics, COMSATS University Islamabad, Wah Cantt, Pakistan; 3Department of Mathematics, COMSATS University Islamabad, Lahore 54000, Pakistan; 4Institute of Systems Engineering, Macau University of Science and Technology, Taipa, Macau; 5School of Electro-Mechanical Engineering, Xidian University, Xi’an 710071, China; 6Fluid Mechanics, Spray Research Group, Mechanical and Petroleum Engineering, School of Computing, Science and Engineering, G77, University of Salford, Manchester M54WT, UK
Background: Controlled inhibition of kinesin motor proteins is highly desired in the field of oncology. Among other interventions, there exists “targeted chemotherapeutic regime/options” of selective Eg5 competitive and allosteric inhibitors, inducing cancer cell apoptosis and tumor regression with improved safety profiles.
Research question: Though promising, such studies are still under clinical trials, for the discovery of efficient and least harmful Eg5 inhibitors. The aim of this research was to bridge the computational modeling approach with drug design and therapy of cancer cells.
Methods: A computational model, interfaced with the clinical data of “Eg5 dynamics” and “inhibitors” via special functions, is presented in this article. Comparisons are made for the drug efficacy, and the threshold values are predicted through numerical simulations.
Results: Results are obtained to depict the dynamics induced by ispinesib, when used as an inhibitor of kinesin Eg5, on cancer cell lines.
Keywords: drug efficient model, bipolar spindle, Eg5, cancer, mitotic arrest, Eg5 inhibitors
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]